Maiva Pharma Secures Rs 1,000 Crore From Morgan Stanley PE And India Life Sciences Fund

Complex injectables development and manufacturing capability, strong compliance and regulatory standards, along with transparency and leadership, differentiate Maiva from its competitors, Sumit Gupta, managing director of Invascent, which acts as the investment manager to India Life Sciences Fund IV, said.

Leave a Comment